| Autor: |
Damla, Uludağ, Sadık, Bay, Bilgesu Onur, Sucu, Özgecan, Şavluğ İpek, Thomas, Mohr, Mustafa, Güzel, Nihal, Karakaş |
| Rok vydání: |
2021 |
| Zdroj: |
Frontiers in pharmacology. 13 |
| ISSN: |
1663-9812 |
| Popis: |
Change in the energy metabolism of cancer cells, which display significant differences compared to normal cells, is a rising phenomenon in developing new therapeutic approaches against cancers. One of the metabolic enzymes, hexokinase-II (HK-II) is involved in glycolysis, and inhibiting the HK-II activity may be a potential metabolic target for cancer therapy as most of the drugs in clinical use act on DNA damage. Methyl jasmonate (MJ) is one of the compounds blocking HK-II activity in cancer cells. In a previous study, we showed that the novel MJ analogs inhibit HK-II activity through VDAC detachment from the mitochondria. In this study, to evaluate the potential of targeting HK-2 activity, through patient cohort analysis, we first determined HK-2 expression levels and prognostic significance in highly lethal glioblastoma (GBM) brain tumor. We then examined the |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
